00881.HK
Zhongsheng Group Holdings Limited
HKSE · Consumer Cyclical · Auto - Dealerships · CN
HKD 3.62
−0.55%Sep 2, 2026, 09:52 UTC
Zhongsheng Pharmaceutical's subsidiary Guangdong Zhongsheng Ruichuang Biotech received NMPA acceptance of its clinical trial application for a new indication of Anguradvir tablets to treat high-risk influenza A, planning a Phase III study.
Source:Aug 31, 2026, 10:48 UTC
Zhongsheng Group opened 62 new energy vehicle stores in the first half of 2026, bringing its total new energy brand stores to 102, and plans to reach 300 by the end of 2026.
Source:Aug 31, 2026, 04:12 UTC
Zhongsheng Group Holdings announced its interim results for the six months ended June 2026, with net profit falling 89.1% year-on-year to RMB 111 million.
Source:Aug 6, 2026, 04:18 UTC
Zhongsheng Group repurchased US$117.91 million of its 5.98% bonds due January 2028 in the open market and cancelled them, reducing outstanding principal to US$482.09 million.
Source:Aug 5, 2026, 22:30 UTC
Zhongsheng Group Holdings Limited's shares traded 1% higher on Monday, reaching $6.00 with unusually low volume.
Source: